On the basis of 26 studies about Bcl-2 -938C>A polymorphism and cancer, we found Bcl-2 -938 C>A polymorphism was significantly associated with increased cancer risk in dominant model (OR = 1.12, 95%CI: 1.00–1.25, P = 0.04), recessive model (OR = 1.38, 95%CI: 1.11–1.71, P = 0.004), allelic model (OR = 1.15, 95%CI: 1.04–1.28, P = 0.007) and homozygote comparison(OR = 1.44, 95%CI: 1.11–1.87, P = 0.006). This evidence concerns the gene BCL2 and cancer.